Literature DB >> 29478365

Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population.

Haoyu Wang1, Yintao Chen1, Guozhe Sun1, Pengyu Jia1, Hao Qian1, Yingxian Sun1.   

Abstract

OBJECTIVES: Adiposity, defined by higher cardiometabolic index (CMI), lipid accumulation product (LAP), and body adiposity index (BAI), has conferred increased metabolic risk. However, the incremental utility of CMI, LAP, and BAI in association with prevalent hypertension has not been well described in a population-based setting. We hypothesized that CMI, LAP, and BAI would provide important insight into hypertension risk.
METHODS: Blood pressure (BP), fasting lipid profiles, and anthropometric parameters were recorded in a cross-sectional study of 11,400 participants (mean age, 54 years; 53% women) from China. Logistic regression models were used to assess associations of CMI, LAP, and BAI with prevalent hypertension. BAI was evaluated according to hip (cm)/[height (m)1.5]-18; LAP was calculated separately for men [(WC-65) × TG] and women [(WC-58) × TG]; and CMI was defined by TG/HDL-C × waist-to-height ratio.
RESULTS: CMI, LAP, and BAI were independently correlated with higher SBP and DBP, with nonstandardized (B) coefficients ranging from 1.827 to 4.590 mmHg and 1.475 to 2.210 mmHg (all P < 0.001). After adjustment for hypertension risk factors and potential confounders, CMI, LAP, and BAI, modeled as continuous measures, carried hypertension odds (95% CI) of 1.356 (1.259-1.459), 1.631 (1.501-1.771), and 1.555 (1.454-1.662) in women, respectively, per SD increment. In men, each SD increase in CMI, LAP, and BAI experienced a 31%, 65%, and 53% higher hypertension risk, respectively. Moreover, among women, the odds ratio (95% CI) for hypertension were 2.318 (1.956-2.745), 3.548 (2.985-4.217), and 3.004 (2.537-3.557) in the 4th quartile vs the first quartile of CMI, LAP, and BAI, respectively. For men, the corresponding figures were 2.200 (1.838-2.635), 3.892 (3.238-4.677), and 3.288 (2.754-3.927), respectively.
CONCLUSION: Measurements of CMI, LAP, and BAI provide a more complete understanding of hypertension risk related to variation in body fat distribution and pinpoint hypertensive participants in great risk of cardiovascular disease in the future.

Entities:  

Keywords:  Hypertension; adiposity; body adiposity index; cardiometabolic index; epidemiology; lipid accumulation product

Mesh:

Substances:

Year:  2018        PMID: 29478365     DOI: 10.1080/00325481.2018.1444901

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  17 in total

1.  Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype.

Authors:  X Liu; Q Wu; G Yan; J Duan; Z Chen; P Yang; N L Bragazzi; Y Lu; H Yuan
Journal:  J Endocrinol Invest       Date:  2020-09-09       Impact factor: 4.256

2.  Which anthropometric and metabolic index is superior in hypertension prediction among overweight/obese adults?

Authors:  Maryam Abolhasani; Nastaran Maghbouli; Jemal Haidar Ali; Shahrokh Karbalai Saleh; Ziba Aghsaeifar; Faeze Sazgara; Maryam Tahmasebi; Haleh Ashraf
Journal:  Integr Blood Press Control       Date:  2021-11-08

3.  Urine Glucose Excretion Attenuates the Association Between Lipid Accumulation Product and Serum Uric Acid in Subjects with Prediabetes.

Authors:  Juan Chen; Yu Liu; Haijian Guo; Bei Wang; Zilin Sun; Jiangyi Yu
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-30       Impact factor: 3.168

4.  Estimate of prevalent diabetes from cardiometabolic index in general Chinese population: a community-based study.

Authors:  Wen-Rui Shi; Hao-Yu Wang; Shuang Chen; Xiao-Fan Guo; Zhao Li; Ying-Xian Sun
Journal:  Lipids Health Dis       Date:  2018-10-12       Impact factor: 3.876

5.  Association of Obesity Measures with Atrial Fibrillation Recurrence After Cryoablation in Patients with Paroxysmal Atrial Fibrillation.

Authors:  Luxiang Shang; Mengjiao Shao; Qilong Guo; Jiasuoer Xiaokereti; Yang Zhao; Yanmei Lu; Ling Zhang; Baopeng Tang; Xianhui Zhou
Journal:  Med Sci Monit       Date:  2020-02-27

6.  Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals.

Authors:  Yan Zhang; Bo Li; Nan Liu; Peixi Wang; Jinghua He
Journal:  Int J Endocrinol       Date:  2021-01-27       Impact factor: 3.257

7.  Serum endocan levels in relation to traditional and non-traditional anthropometric indices in adult population.

Authors:  Aleksandra Klisić; Nebojša Kavarić; Vesna Spasojević-Kalimanovska; Jelena Kotur-Stevuljević; Ana Ninić
Journal:  J Med Biochem       Date:  2021-01-26       Impact factor: 3.402

8.  Age-adjusted cut-off values of lipid accumulation product (LAP) for predicting hypertension.

Authors:  Anastasiya M Kaneva; Evgeny R Bojko
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

9.  Value of reduced glomerular filtration rate assessment with cardiometabolic index: insights from a population-based Chinese cohort.

Authors:  Hao-Yu Wang; Wen-Rui Shi; Xin Yi; Shu-Ze Wang; Si-Yuan Luan; Ying-Xian Sun
Journal:  BMC Nephrol       Date:  2018-10-25       Impact factor: 2.388

10.  Interaction of lipid accumulation product and family history of hypertension on hypertension risk: a cross-sectional study in the Southern Chinese population.

Authors:  JunXuan Huang; XinYu Bao; YiXian Xie; XiaoXia Zhang; Xin Peng; Yan Liu; MengJiao Cheng; JinXiang Ma; PeiXi Wang
Journal:  BMJ Open       Date:  2019-11-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.